HIF1A and pancreatic neoplasm: To identify inhibitors of HIF-2α, we performed a high throughput screening campaign of the 360,000 compound NIH Molecular Libraries Probe Production Centers Network (MLPCN) using a hypoxia-responsive element (HRE)-luciferase based screen in 786-0 RCC cells (express HIF-2α exclusively), followed by a counter-screen using deferoxamine-treated MIA-PaCa2 pancreatic cancer cells (express HIF-1α exclusively).